Arsenic exacerbates atherosclerotic lesion formation and inflammation in ApoE-/- mice.
Exposure to arsenic-contaminated water has been shown to be associated with cardiovascular disease, especially atherosclerosis. We examined the effect of arsenic exposure on atherosclerotic lesion formation, lesion composition and nature in ApoE-/- mice. Early post-natal exposure (3-week-old mice exposed to 49 ppm arsenic as NaAsO(2) in drinking water for 7 weeks) increased the atherosclerotic lesion formation by 3- to 5-fold in the aortic valve and the aortic arch, without affecting plasma cholesterol. Exposure to arsenic for 13 weeks (3-week-old mice exposed to 1, 4.9 and 49 ppm arsenic as NaAsO(2) in drinking water) increased the lesion formation and macrophage accumulation in a dose-dependent manner. Temporal studies showed that continuous arsenic exposure significantly exacerbated the lesion formation throughout the aortic tree at 16 and 36 weeks of age. Withdrawal of arsenic for 12 weeks after an initial exposure for 21 weeks (to 3-week-old mice) significantly decreased lesion formation as compared with mice continuously exposed to arsenic. Similarly, adult exposure to 49 ppm arsenic for 24 weeks, starting at 12 weeks of age increased lesion formation by 2- to 3.6-fold in the aortic valve, the aortic arch and the abdominal aorta. Lesions of arsenic-exposed mice displayed a 1.8-fold increase in macrophage accumulation whereas smooth muscle cell and T-lymphocyte contents were not changed. Expression of pro-inflammatory chemokine MCP-1 and cytokine IL-6 and markers of oxidative stress, protein-HNE and protein-MDA adducts were markedly increased in lesions of arsenic-exposed mice. Plasma concentrations of MCP-1, IL-6 and MDA were also significantly elevated in arsenic-exposed mice. These data suggest that arsenic exposure increases oxidative stress, inflammation and atherosclerotic lesion formation.
Srivastava
Sanjay
S
Diabetes and Obesity Center and Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40202, USA. sanjay@louisville.edu
Vladykovskaya
Elena N
EN
Haberzettl
Petra
P
Sithu
Srinivas D
SD
D'Souza
Stanley E
SE
States
J Christopher
JC
D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects / Q000378:metabolism; D001021:Aortic Valve / Q000187:drug effects / Q000378:metabolism; D001057:Apolipoproteins E / Q000235:genetics*; D018053:Arsenites / Q000008:administration & dosage / Q000633:toxicity*; D050197:Atherosclerosis / Q000139:chemically induced*; D004305:Dose-Response Relationship, Drug; D007249:Inflammation / Q000139:chemically induced*; D008264:Macrophages / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects*; D017670:Sodium Compounds / Q000008:administration & dosage / Q000633:toxicity*; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D013997:Time Factors
D001057:Apolipoproteins E; D018053:Arsenites; D017670:Sodium Compounds; C017947:sodium arsenite
Environ Health Perspect. 2005 Mar;113(3):339-41
15743725
Environ Health Perspect. 2006 Aug;114(8):1293-6
16882542
Mol Cell. 1998 Aug;2(2):275-81
9734366
Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8264-8
7667279
Arterioscler Thromb Vasc Biol. 1999 Jun;19(6):1518-25
10364084
Free Radic Biol Med. 1999 Dec;27(11-12):1405-12
10641735
Circulation. 2002 Apr 16;105(15):1804-9
11956123
Circulation. 1973 Feb;47(2):270-5
4684927
Arch Pathol. 1974 Jun;97(6):360-5
4825098
J Cell Biol. 1985 Mar;100(3):965-73
3972906
Environ Health Perspect. 2001 Oct;109(10):1011-7
11675266
Toxicol Appl Pharmacol. 2008 Feb 15;227(1):1-7
18022660
J Expo Anal Environ Epidemiol. 2003 May;13(3):231-9
12743617
Circulation. 1996 Sep 1;94(5):874-7
8790019
Am J Physiol Heart Circ Physiol. 2002 Dec;283(6):H2612-9
12388223
Circulation. 2004 Jun 1;109(21 Suppl 1):II2-10
15173056
Cardiovasc Res. 2007 Jun 1;74(3):445-55
17362897
J Cell Physiol. 1998 Nov;177(2):324-33
9766529
Epidemiol Rev. 1994;16(2):184-209
7713176
Toxicol Sci. 2009 Feb;107(2):312-23
19015167
Diabetes. 2006 Apr;55(4):901-10
16567509
Science. 2002 Jun 21;296(5576):2145-6
12077388
Atherosclerosis. 2008 Jul;199(1):12-8
18367191
Atherosclerosis. 1999 Mar;143(1):205-11
10208497
Chem Biol Interact. 2008 May 28;173(2):129-40
18396267
J Immunol. 2007 Jul 1;179(1):313-21
17579051
Free Radic Biol Med. 2008 Jul 15;45(2):119-23
18460347
Reprod Toxicol. 2007 Apr-May;23(3):449-56
17317095
Arterioscler Thromb Vasc Biol. 2003 Jul 1;23(7):1255-61
12775578
Atherosclerosis. 1998 Dec;141(2):249-57
9862173
Arterioscler Thromb Vasc Biol. 1996 Apr;16(4):504-10
8624771
Nat Med. 2002 Nov;8(11):1235-42
12411950
Environ Health Perspect. 2003 Nov;111(14):1744-8
14594625
Mol Cells. 2008 May 31;25(3):347-51
18483467
Atherosclerosis. 2003 Oct;170(2):223-8
14612201
Toxicol Appl Pharmacol. 2004 Nov 15;201(1):32-9
15519606
Circulation. 1994 Jul;90(1):42-9
8026027
Cardiovasc Res. 2008 Aug 1;79(3):360-76
18487233
Hypertension. 1995 Jan;25(1):53-60
7843753
Toxicol Appl Pharmacol. 2007 Aug 1;222(3):315-26
17433393
Environ Health Perspect. 2003 Aug;111(11):1429-38
12928151
Science. 2002 Jun 21;296(5576):2143-5
12077387
Atherosclerosis. 1998 May;138(1):147-52
9678780
Science. 2006 Dec 15;314(5806):1687-8
17170279
Circulation. 2004 Jun 15;109(23 Suppl 1):III2-7
15198959